European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

4 EU fundings (total €620,374): 899991 - Rita-MI 2 - Rituximab in Patients with Acute Myocardial Infarction: a Phase 2 Placebo-Controlled Randomised Clinical Trial … BdlYear 2021 Financial Transparency System

Text

Inserm Transfert SA, Paris, France

01/06/2021 EU funding (€16,673.10): 899991 - Rita-MI 2 - Rituximab in Patients with Acute Myocardial Infarction: a Phase 2 Placebo-Controlled Randomised Clinical Trial
01/03/2021 EU funding (€212,799): 964049 - Cbig-Screen - Working Collaboratively with Vulnerable Women to Identify the Best Implementation Gains by Screening Cervical Cancer More Effectively in European Countries
01/06/2021 EU funding (€349,202): 899991 - Rita-MI 2 - Rituximab in Patients with Acute Myocardial Infarction: a Phase 2 Placebo-Controlled Randomised Clinical Trial
01/03/2021 EU funding (€41,700): 964049 - Cbig-Screen - Working Collaboratively with Vulnerable Women to Identify the Best Implementation Gains by Screening Cervical Cancer More Effectively in European Countries
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

This filing was translated from to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Inserm Transfert SA, Paris, France.

Creative Commons License The visualizations for "Inserm Transfert SA - 4 EU fundings (total €620,374): 899991 - Rita-MI 2 - Rituximab in Patients with Acute Myocardial Infarction: a Phase 2 Placebo-Controlled Randomised Clinical Trial …" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close